Table 2

Blood Markers

Baseline6 Months12 Months
Total-C (mg/dl)
 NA153 ± 32141 ± 25147 ± 26
 Placebo161 ± 42159 ± 35154 ± 25
 p value0.0030.06
HDL-C (mg/dl)
 NA39 ± 646 ± 948 ± 7
 Placebo37 ± 536 ± 638 ± 6
 p value<0.001<0.001
LDL-C (mg/dl)
 NA85 ± 2364 ± 1669 ± 21
 Placebo84 ± 3280 ± 2880 ± 22
 p value0.0020.01
Triglycerides (mg/dl)
 NA168 (134–206)150 (91–190)150 (94–180)
 Placebo192 (132–248)182 (144–248)181 (143–252)
 p value0.020.02
Lp(a) (mg/dl)
 NA14 (7–44)10 (7–38)9 (5–28)
 Placebo14 (7–53)18 (6–49)18 (6–49)
 p value0.040.003
apo B (g/l)
 NA0.82 ± 0.170.70 ± 0.130.73 ± 0.14
 Placebo0.84 ± 0.210.80 ± 0.190.82 ± 0.14
 p value0.010.003
apo AI (g/l)
 NA1.27 ± 0.161.29 ± 0.201.32 ± 0.17
 Placebo1.20 ± 0.141.19 ± 0.161.18 ± 0.16
 p value0.20.1
CRP (mg/l)
 NA12.9 (4.4–18.8)12.1 (3.7–18.0)5.7 (3.2–14.1)
 Placebo12.4 (3.8–3.2)14.0 (4.6–27.5)12.2 (5.1–23.8)
 p value0.030.1
Adiponectin (mμ/ml)
 NA10.0 ± 6.818.5 ± 15.019.4 ± 16.8
 Placebo8.6 ± 6.810.0 ± 9.411.0 ± 11.0
 p value0.0010.002
HbA1c (%)
 NA6.9 (6.2–8.2)7.0 (6.0–8.2)6.7 (6.0–8.5)
 Placebo7.4 (6.8–8.0)6.5 (6.0–8.0)6.9 (6.0–8.2)
 p value0.020.07

apo = apolipoprotein; CRP = C-reactive protein; HbA1c= glycosylated hemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; Lp(a) = lipoprotein(a); NA = nicotinic acid; Total-C = total cholesterol.

  • Summary statistics reported as mean ± SD or median (interquartile range);

  • p values derived from mixed-effect model on outcomes defined as change from 6 (or 12 months) from baseline, adjusting for baseline prognostic covariates;

  • analysis was carried out on log-transformed data.